TY - JOUR
T1 - My Lived Experiences Are More Important Than Your Probabilities
T2 - The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR)
AU - Holmberg, Christine
AU - Waters, Erika A.
AU - Whitehouse, Katie
AU - Daly, Mary
AU - McCaskill-Stevens, Worta
N1 - Publisher Copyright:
© 2015 Society for Medical Decision Making.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Background: Decision-making experts emphasize that understanding and using probabilistic information are important for making informed decisions about medical treatments involving complex risk-benefit tradeoffs. Yet empirical research demonstrates that individuals may not use probabilities when making decisions. Objectives: To explore decision making and the use of probabilities for decision making from the perspective of women who were risk-eligible to enroll in the Study of Tamoxifen and Raloxifene (STAR). Methods: We conducted narrative interviews with 20 women who agreed to participate in STAR and 20 women who declined. The project was based on a narrative approach. Analysis included the development of summaries of each narrative, and thematic analysis with developing a coding scheme inductively to code all transcripts to identify emerging themes. Results: Interviewees explained and embedded their STAR decisions within experiences encountered throughout their lives. Such lived experiences included but were not limited to breast cancer family history, a personal history of breast biopsies, and experiences or assumptions about taking tamoxifen or medicines more generally. Conclusions: Womens explanations of their decisions about participating in a breast cancer chemoprevention trial were more complex than decision strategies that rely solely on a quantitative risk-benefit analysis of probabilities derived from populations In addition to precise risk information, clinicians and risk communicators should recognize the importance and legitimacy of lived experience in individual decision making.
AB - Background: Decision-making experts emphasize that understanding and using probabilistic information are important for making informed decisions about medical treatments involving complex risk-benefit tradeoffs. Yet empirical research demonstrates that individuals may not use probabilities when making decisions. Objectives: To explore decision making and the use of probabilities for decision making from the perspective of women who were risk-eligible to enroll in the Study of Tamoxifen and Raloxifene (STAR). Methods: We conducted narrative interviews with 20 women who agreed to participate in STAR and 20 women who declined. The project was based on a narrative approach. Analysis included the development of summaries of each narrative, and thematic analysis with developing a coding scheme inductively to code all transcripts to identify emerging themes. Results: Interviewees explained and embedded their STAR decisions within experiences encountered throughout their lives. Such lived experiences included but were not limited to breast cancer family history, a personal history of breast biopsies, and experiences or assumptions about taking tamoxifen or medicines more generally. Conclusions: Womens explanations of their decisions about participating in a breast cancer chemoprevention trial were more complex than decision strategies that rely solely on a quantitative risk-benefit analysis of probabilities derived from populations In addition to precise risk information, clinicians and risk communicators should recognize the importance and legitimacy of lived experience in individual decision making.
KW - Adult
KW - Aged
KW - Antineoplastic Agents, Hormonal/therapeutic use
KW - Breast Neoplasms/prevention & control
KW - Chemoprevention/methods
KW - Decision Making
KW - Estrogen Antagonists/therapeutic use
KW - Female
KW - Health Knowledge, Attitudes, Practice
KW - Humans
KW - Interviews as Topic
KW - Middle Aged
KW - National Cancer Institute (U.S.)
KW - Probability
KW - Raloxifene Hydrochloride/therapeutic use
KW - Risk Assessment/methods
KW - Tamoxifen/therapeutic use
KW - United States
UR - http://www.scopus.com/inward/record.url?scp=84942879358&partnerID=8YFLogxK
U2 - 10.1177/0272989X15594382
DO - 10.1177/0272989X15594382
M3 - Article
C2 - 26183166
AN - SCOPUS:84942879358
SN - 0272-989X
VL - 35
SP - 1010
EP - 1022
JO - Medical Decision Making
JF - Medical Decision Making
IS - 8
ER -